检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘欢[1] 李向平[1] 赵水平[1] 胡松[1] 周宏年[1]
机构地区:[1]中南大学湘雅二医院心内科,湖南长沙410011
出 处:《中国实用内科杂志》2007年第22期1767-1769,共3页Chinese Journal of Practical Internal Medicine
基 金:湖南省科技厅计划项目(05FJ4056)
摘 要:目的探讨冠心病患者血清载脂蛋白A5(APOA5)与脂联素和空腹胰岛素(FINS)之间的关系。方法检测2005年6月至12月在中南大学湘雅二医院心内科住院确诊的51例冠心病患者和同期在此院门诊进行健康体检的44名健康对照者血清APOA5、脂联素、FINS和血脂,并计算胰岛素抵抗指数(HOMA-IR)。结果冠心病组血清APOA5和脂联素显著低于健康对照组[(230.06±115.80)μg/L对(324.43±151.79)μg/L,(3.03±1.85)mg/L对(4.12±2.48)mg/L,P均<0.05];冠心病组的FINS显著高于对照组[(9.85±5.94)mU/L对(7.85±3.04)mU/L,P<0.05]。APOA5与三酰甘油(TG)、FINS、HOMA-IR呈负相关,与高密度脂蛋白胆固醇(HDL-C)呈正相关,与脂联素不相关。结论冠心病患者血清APOA5和脂联素降低,FINS增高。APOA5不但影响血脂代谢,而且可能与胰岛素抵抗有关。Objective To explore the change of serum concentrations of apolipoprotein A5 ( APOA5), and the relationship with levels of adiponectin and fasting insulin (FINS) in patients with coronary heart disease (CHD), Methods Blood lipids, the serum concentrations of APOA5 ,adiponectin and insulin were examined in 95 individuals,who were divided into two groups:51 patients with CHD and 44 healthy individuals. Results The concentrations of APOA5 and adiponectin in CHD patients were significantly lower than the healthy individuals[ (230. 06 + 115. 8) μg/L and(3. 03 + 1. 85 ) μgL vs (324. 43 + 151. 79 ) μg/L and (4. 12 + 2. 48 ) μg/L respectively, all P 〈 0. 05 ] ;whereas insulin levels were significantly higher than the healthy individuals [ (9. 85 + 5. 94 ) mU/L vs ( 7. 85 + 3. 04 ) mU/L respectively, P 〈 0. 05 ], Plasma APOA5 was negatively correlated with FINS and triglyceride, but positively correlated with HDL-C;no correlation was found with adiponectin. Conclusion The patients with CHD have decreased serum levels of APOA5 and adiponectin.but increased levels of FINS, APOA5 can influence blood lipids, which may partly attribute to the effects of insulin resistance.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117